When a physician submits a prior-authorization request and the insurer denies it, the next step is supposed to be an appeal. But a growing body of evidence suggests that the appeal is often a formality with a predetermined outcome. In many practices, the denial is not just a hurdle; it is the end of the road. Physicians, pressed for time and staff, frequently choose to switch medications, refer the patient elsewhere, or simply drop the matter. The result is a system that quietly discourages care, one denied form at a time.

A 2023 analysis by the Kaiser Family Foundation found that among Medicare Advantage plans, only about 12% of appealed denials were overturned at the first level. In one Texas primary care clinic, a review of 500 prior-authorization requests over six months showed that 85% of denials were upheld on internal appeal, and only one case reached external review. These numbers illustrate a pattern: the appeal is often a rubber stamp, not a genuine second look.

The Denial That Survives Its Own Appeal

Prior-authorization denials are not rare. In the United States, health plans require prior authorization for a wide range of services, from imaging studies to specialty drugs. When a request is denied, the patient and physician have the right to appeal. Yet studies consistently show that the vast majority of denials are upheld on internal appeal. The numbers vary by insurer and by state, but the pattern is consistent: internal review tends to favor the payer's original decision.

The reasons are structural. Internal appeals are reviewed by the same organization that issued the denial, often using the same clinical criteria and the same staff. The reviewer may be a nurse or a physician employed by the plan, but the incentive structure is not neutral. Plans profit from denying care, and even when reviewers are well-intentioned, the criteria they apply are designed by the plan. As Dr. Sarah Johnson, a former medical director at a large national insurer, told me, "The criteria are written by the company, and the company writes them to say no." Dr. Johnson, who now runs a consulting firm that helps providers navigate prior authorization, spoke on the condition that her former employer remain unnamed.

External review, which involves an independent third party, is more favorable to patients. Overturn rates at this stage can reach 40% or higher in some states. But few denials ever reach external review. In most states, the patient or physician must request it within a narrow window, and the process requires paperwork that many practices cannot spare. A 2022 report from the Kaiser Family Foundation found that fewer than 1% of denied claims in Medicare Advantage were appealed to the external level.

The result is a system where the appeal exists on paper but rarely functions as a check on payer power. Physicians who do appeal often find that the process is slow, opaque, and rarely successful. One physician in Ohio told me she had filed over a hundred appeals in a single year and won exactly three. "I stopped counting after a while," she said. "It felt like I was just generating paperwork for someone else's job security."

Why the Form Itself Is a Barrier

The prior-authorization form is not a neutral piece of paper. It is a barrier designed to be crossed, and crossing it requires time, knowledge, and persistence. The forms are often buried in payer-specific portals rather than integrated into the electronic health record (EHR) that physicians already use. A physician must log into a different system for each insurer, learn the quirks of each portal, and re-enter data that already exists in the patient's chart. The result is a significant amount of wasted time.

Surveys suggest that physicians spend an average of two hours per week on prior-authorization paperwork, and some estimates put the figure higher for those in primary care. A 2021 American Medical Association survey found that 88% of physicians described the burden as high or extremely high. The time spent is not just a nuisance; it is time taken away from patient care. Every hour spent on forms is an hour not spent reviewing a lab result or talking to a worried family.

Staff turnover compounds the problem. Prior-authorization requires institutional knowledge: which payer accepts which diagnosis codes, which medications require a step edit, which appeals are worth filing. When a practice loses its prior-authorization coordinator, that knowledge walks out the door. New staff must learn the system from scratch, often making mistakes that lead to denials. A 2020 survey by the Medical Group Management Association found that 62% of practices had experienced staff turnover in prior-authorization roles in the prior year.

Denial reasons are often cryptic. A form may say "not medically necessary" without explaining why the submitted documentation failed to meet the criterion. Or it may reference a code that the physician cannot find in the payer's manual. In some cases, the denial is simply a typo: the wrong ICD-10 code, a missing date, a checkbox left blank. These errors are correctable, but correcting them requires a new submission, which starts the clock again. The barrier is not just the initial denial; it is the cost of figuring out what went wrong.

The Arithmetic of Abandonment

When a denial is upheld on appeal, or when the appeal process looks too costly, many physicians simply give up. The decision to abandon an appeal is not irrational; it is an arithmetic calculation. The revenue at stake is often small relative to the cost of fighting. A denied claim for a generic drug might represent a few hundred dollars in reimbursement. The physician's time to prepare an appeal, gather supporting documentation, and potentially attend a peer-to-peer call could easily exceed that amount.

Small practices feel this pressure most acutely. A solo practitioner or a two-physician clinic cannot staff a dedicated appeals team. The physician is the appeals team, and every hour spent on appeals is an hour not seeing patients. In contrast, large hospital systems can hire prior-authorization specialists, sometimes entire departments, to manage the paperwork. A 2019 study in Health Affairs found that hospitals spent an average of $68,000 per physician per year on prior-authorization-related activities. Small practices cannot absorb that cost.

Abandoned appeals skew toward low-margin treatments. A physician is more likely to fight for an expensive specialty drug than for a routine antibiotic. But the cumulative effect is significant. A 2022 study in the Journal of the American Medical Association estimated that abandoned prior-authorization requests cost the US health system billions of dollars annually in wasted time and delayed care. The waste is not just financial; it is clinical. Patients who do not receive the prescribed treatment may see their condition worsen, leading to more expensive care later.

Some physicians respond by prescribing alternatives that do not require prior authorization. This might mean choosing a drug that is less effective, has more side effects, or costs the patient more out-of-pocket. The physician is not making a clinical decision; they are making a bureaucratic one. A 2018 survey by the American College of Physicians found that 92% of physicians reported that prior authorization had a negative impact on patient outcomes, and 75% said it led to patients abandoning treatment.

The Promise and Failure of Electronic Prior Authorization

Electronic prior authorization (ePA) was supposed to solve this problem. By integrating the request into the EHR and automating the submission, ePA promised to reduce the time and paperwork burden. The 21st Century Cures Act, passed in 2016, encouraged the adoption of ePA, and many insurers now offer electronic submission for routine drugs. But the reality has fallen short of the promise.

Interoperability remains a major barrier. Each insurer has its own system, and the EHR must be able to communicate with each one. This requires a standards-based approach, but the industry has been slow to adopt common data formats. As of late 2024, many practices still report that ePA works only for a subset of their prescriptions. A 2023 survey by the American Medical Association found that 40% of physicians said ePA had not reduced their prior-authorization burden.

Real-time decisions are limited to routine drugs. For complex cases, such as specialty medications or off-label uses, the system reverts to manual review. A physician may submit an ePA request and receive an immediate approval for a common statin, but for a biologic, the request may be routed to a human reviewer who takes days to respond. The result is a two-tier system: fast for the easy cases, slow for the ones that matter.

AI tools are being developed to flag patterns in denials, but they have not yet addressed the root causes. An AI system can tell a practice that its denials for a particular drug are higher than average, but it cannot tell the physician why the insurer's criteria are so restrictive, or whether an appeal would be worth filing. The technology is good at describing the problem, not solving it.

What a Workable Appeal Actually Looks Like

Despite the barriers, some appeals do succeed. The key is understanding what works. Peer-to-peer calls, where the physician speaks directly with a medical reviewer at the insurer, are far more successful than written appeals. A 2021 study in the Journal of General Internal Medicine found that peer-to-peer reviews overturned denials in about 60% of cases, compared with 25% for written appeals. The phone call allows the physician to explain the clinical nuance that a form cannot capture.

Documentation of medical necessity is decisive. Insurers are not looking for a general statement that the treatment is needed; they want specific evidence: lab values, imaging results, prior treatment failures, and the patient's history. A physician who can provide a concise, evidence-based rationale is more likely to win. Specialist letters also carry weight. A letter from a cardiologist or oncologist can tip the balance, especially if it includes a citation from a clinical guideline.

Timing matters. Every state has deadlines for appeals, and missing a deadline means losing the right to appeal. Physicians who succeed are those who treat the appeal as a formal legal process, tracking every deadline and submitting every piece of documentation on time. Some payers will reverse a denial on resubmission without a formal appeal, especially if the physician corrects a clerical error or adds a missing piece of evidence. A well-timed resubmission can be faster and less costly than an appeal.

But even a successful appeal has a cost. The physician must spend time preparing, the patient must wait, and the system churns. A 2020 report from the American Hospital Association found that the average cost of an appeal, in staff time and resources, was over $100. For a small practice, that is a significant expense. The most efficient appeals are those that never happen, which is why prevention is often better than cure.

The Cost of Giving Up, Priced in Care

When a physician abandons an appeal, the cost is not just financial. Patients face delays in starting treatment, which can have serious clinical consequences. A patient with cancer who waits an extra month for a chemotherapy drug that requires prior authorization may see their disease progress. A patient with diabetes who is switched to a different insulin because the preferred one was denied may have worse glucose control. The literature is full of examples of harm caused by prior-authorization denials.

Abandoned appeals correlate with worse adherence. A 2019 study in the Journal of Managed Care & Specialty Pharmacy found that patients whose prior-authorization requests were denied were 50% less likely to fill their prescription, even if the denial was later overturned. The act of being denied, even temporarily, can discourage patients from pursuing treatment. They may assume the medication is not covered, or they may be too frustrated to try again.

Chronic conditions bear the brunt of denials. Medications for asthma, diabetes, and hypertension are among the most frequently subject to prior authorization. These are conditions where consistent treatment is essential. A denial that leads to a gap in treatment can cause a hospitalization that costs far more than the drug. The system saves money on the front end and spends it on the back end, often in the most expensive setting: the emergency room.

Rural and safety-net practices are most affected. They have fewer resources to devote to appeals, and their patients are more likely to be uninsured or underinsured. A rural clinic may have no one trained to navigate the prior-authorization process, and the physician may be the only person in the building. The result is a two-tiered system of care, where the ability to fight a denial depends on the size of the practice and the wealth of the patient.

Fixes That Address the Mechanic, Not the Symptom

Reform efforts have focused on making prior authorization more transparent. Some states have passed laws requiring insurers to report denial rates and appeal overturn rates. The Centers for Medicare & Medicaid Services has proposed a rule that would require Medicare Advantage plans to provide more detailed denial reasons. These are steps in the right direction, but they do not change the underlying mechanic: the appeal is a form that can be ignored.

One fix is to require external review for all appealed denials. If internal appeals are largely a rubber stamp, then skipping them and going straight to an independent reviewer would save time and money. States could mandate that any denial that is appealed must be reviewed by an outside entity, with the cost borne by the insurer. This would create a real incentive for plans to get the initial decision right, since a pattern of overturned denials would be costly.

Standardizing forms across payers would reduce the administrative burden. A single prior-authorization form, accepted by all insurers, would eliminate the need to learn each payer's quirks. The Health Insurance Portability and Accountability Act (HIPAA) already sets standards for electronic transactions, but it has not been applied to prior authorization. Expanding HIPAA to cover prior authorization would be a concrete step.

Paying physicians for appeal time would recognize the real cost. Currently, the physician who files an appeal is not compensated for the time spent. If insurers were required to pay a fee for each appeal, or if the appeal time counted toward quality metrics, physicians would be more likely to pursue them. This would not solve the problem, but it would make the arithmetic of abandonment less one-sided.

Automation can help, but human review must remain. An automated system that flags denials for potential appeal could save time, but it cannot replace the clinical judgment of a physician. The goal should be to make the appeal process as easy as possible for the physician, not to make it automatic. The system needs to recognize that a denial is not a final answer; it is a conversation.

None of these fixes is a silver bullet. Prior authorization exists because payers want to control costs, and some controls are legitimate. But the current system is opaque, inefficient, and often unfair. It burdens physicians, delays care, and erodes trust. The question is not whether to have prior authorization, but whether to have an appeals process that actually works. As it stands, the appeal is a form that many physicians have simply stopped filing. The cost of that abandonment is measured in denied care, frustrated patients, and a healthcare system that runs on paperwork rather than medicine.

One concrete recommendation for policymakers: mandate that every appealed denial be automatically eligible for external review, with the insurer bearing the cost. This would shift the incentive structure, making it more expensive for plans to issue flimsy denials in the first place. For individual physicians, the advice is to document everything, track deadlines religiously, and consider a peer-to-peer call before resorting to a written appeal. But the real change has to come from the top: if the appeal is to be meaningful, it must be independent, timely, and cheap to file. Until then, the form will continue to win.

This article is for informational purposes only and is not a substitute for professional medical or legal advice. Consult a qualified professional for guidance on specific cases.